1. Executive Summary (Confidence: High)

LimmaTech Biologics, based in Schlieren (Zurich), is a global pioneer in the fight against the escalating epidemic of antimicrobial resistance (AMR). Spun out from GlycoVaxyn after that company’s acquisition by GSK in 2015, LimmaTech has maintained a dominant track record in vaccine technology, recently securing a $37 million Series A financing (extended to $40 million) to advance its proprietary pipeline. The organization’s most significant asset is its tetravalent Shigella vaccine (S4V2), which is currently the most clinically advanced of its kind worldwide. In August 2024, LimmaTech entered into a strategic licensing agreement with Valneva, receiving a €10 million upfront payment and eligibility for an additional €40 million in milestones, alongside low double-digit royalties. This partnership validates LimmaTech’s bioconjugate platform as a leading solution for pathogens that have become resistant to traditional antibiotics. The following table summarizes the company’s current pipeline status.